Radiation Oncologists, P.A. has cultivated a culture of innovation and an openness to adopting new tools that provide added precision in patient care. The ArteraAI Prostate Test, offering predictive and prognostic insights, aligns with this forward-thinking approach, particularly in guiding decisions around ST-ADT for intermediate-risk prostate cancer patients.
Related Articles
ArteraAI Achieves SOC 2 Type II Security Compliance Certification
ArteraAI x SOC 2 As part of our commitment to cybersecurity, we are proud to announce that ArteraAI is now SOC 2 Type II cert [...]
ArteraAI Predictive Models
ArteraAI is a leading precision medicine company developing AI tests to personalize cancer therapy. Download the pdf.